This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why Centene (CNC) is a Strong Value Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Centene (CNC) Expands CHS Network, Shifts AcariaHealth Facility
by Zacks Equity Research
Centene's (CNC) subsidiaries, CHS and AcariaHealth, enhance patient outcomes with CHS' CIPA entering Virginia and AcariaHealth's pharmacy facility relocating to Chesterfield, thereby expanding CNC's capabilities.
UnitedHealth Unit (UNH) Wins Medicaid Deal to Serve Kansas
by Zacks Equity Research
UnitedHealth Group (UNH) receives a contract from the State of Kansas to provide enhanced care to beneficiaries of the KanCare program and gain a greater Medicaid customer base.
Centene (CNC), Cityblock Partner to Enhance Value-Based Care
by Zacks Equity Research
Centene (CNC) collaborates with Cityblock to provide comprehensive care services to Central Florida's Medicaid members.
Here's Why Centene (CNC) is a Strong Momentum Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Centene (CNC) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Centene (CNC) to Continue Serving Kansas' Medicaid Members
by Zacks Equity Research
Centene's (CNC) subsidiary wins contract from the Kansas Department of Administration to continue providing comprehensive healthcare services to the KanCare program's members.
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why You Should Retain Centene (CNC) Stock for Now
by Zacks Equity Research
Centene (CNC) remains well-poised for growth on the back of sound growth in membership, divestitures and a growing cash balance.
Brookdale (BKD) Down 3% Post Q1 Earnings: What Lies Ahead?
by Zacks Equity Research
Elevated facility operating costs and lower interest income strain Brookdale's (BKD) Q1 results, which were partly offset by favorable occupancy rates fetching improved resident fees.
Pediatrix (MD) Q1 Earnings Beat on Hospital Contract Fees
by Zacks Equity Research
Pediatrix's (MD) Q1 results benefit from higher same-unit revenues, resulting from growing patient volumes, partly offset by high costs. It continues to expect 2024 adjusted EBITDA within $200-$220 million.
Select Medical's (SEM) Shares Up 12.9% Since Q1 Earnings Beat
by Zacks Equity Research
Select Medical (SEM) revises its adjusted EBITDA guidance upward between $845 million and $885 million for 2024, the mid-point is higher than $807.4 million in 2023.
Acadia Healthcare (ACHC) Shares Down 9% Despite Q1 Earnings Beat
by Zacks Equity Research
Acadia Healthcare's (ACHC) Q1 results aided by improved revenue per patient day, partly offset by escalating costs. It continues to expect 2024 adjusted EPS within $3.40-$3.70.
Zacks Industry Outlook Highlights UnitedHealth, The Cigna, Centene and Humana
by Zacks Equity Research
UnitedHealth, The Cigna, Centene and Humana have been highlighted in this Industry Outlook article.
Ensign Group (ENSG) Stock Down 2.4% Despite Q1 Earnings Beat
by Zacks Equity Research
Ensign Group (ENSG) expects revenues between $4.13 and $4.17 billion, the mid-point of which indicates an improvement of 11.3% from the 2023 figure.
4 HMO Stocks to Watch Amid Persistent Industry Challenges
by Debasmita Chatterjee
The Medical-HMO industry continues to witness an expanding customer base resulting from contract wins. However, high technology expenses and a shortage of medical personnel are a concern. UNH, CI, CNC and HUM are likely to navigate industry storms.
Cigna (CI) Q1 Earnings Beat on Client Wins in Evernorth Unit
by Zacks Equity Research
Cigna's (CI) Q1 results reflect strong organic growth in the Evernorth Health Services unit. It expects adjusted EPS of at least $28.40 for 2024, up from the earlier guidance of at least $28.25.
Should SPDR Russell 1000 Low Volatility Focus ETF (ONEV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for ONEV
Tenet Healthcare (THC) Beats on Q1 Earnings, Ups '24 EPS View
by Zacks Equity Research
Tenet Healthcare's (THC) Q1 results reflect strength in admissions and improved pricing yield. It expects an adjusted EPS of $8.37-$9.41 for 2024, higher than the earlier mentioned $5.76-$6.90.
Why Centene (CNC) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Teladoc Health (TDOC) Q1 Loss Widens on Decline in Visits
by Zacks Equity Research
Teladoc Health's (TDOC) Q1 results suffer from weak contributions from the BetterHelp unit. Management expects U.S. Integrated Care Members of 92-94 million for 2024, up from the prior mentioned 90-92 million.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Centene (CNC) is a Strong Growth Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Centene (CNC) Q1 Earnings Beat on Premiums, '24 EPS View Hiked
by Zacks Equity Research
Centene's (CNC) Q1 results reflect strength in the Commercial business line. Management currently expects adjusted EPS to be greater than $6.80 for 2024.